Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadoteric acid MRI in healthy subjects (HYDROPS)
NCT02529475Phase 4Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Feb 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gadoterate meglumine in Meniere's disease (MD), sponsored by CHU Grenoble Alpes. Started Feb 2016; status: terminated.
02
Drugs
gadoterate meglumine
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02529475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529475.